A new approach to chimeric antigen receptor T-cell therapy has shown great promise against small cell lung cancer in a preclinical study. The findings cover new ground in our understanding of how CAR T can be employed against solid-tumor cancers, and provide support for further studies in cancer patients.
Shanda H. Blackmon was named director of the Lung Institute at Baylor Medicine.
